iguratimod

01/01/2020 - "Iguratimod, a novel immunomodulatory agent for rheumatoid arthritis, has been shown to be effective against murine lupus. "
03/01/2018 - "Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study."
08/24/2018 - "It has been reported that iguratimod is effective and safe for rheumatoid arthritis and other rheumatisms. "
11/15/2013 - "This study may be helpful for further understanding the unique antiarthritic mechanism of iguratimod in patients with rheumatoid arthritis. "
09/01/2019 - "The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis."

07/01/2021 - "Iguratimod attenuates general inflammation, disease activity, and improves lung function in RA-ILD patients."
01/01/2021 - "Iguratimod protected cardiomyocytes through reducing the cascade of inflammation in heart by inhibiting cardiac fibroblast pyroptosis via the COX2/NLRP3 signaling pathway."
01/01/2021 - "However, it is still unclear whether iguratimod could alleviate myocardial I/R injury and whether inflammation triggered by NLRP3-related pyroptosis of CFs is involved in this process. "
01/01/2018 - "The role of iguratimod in intestinal mucosal inflammation and immunity has not been examined. "
09/07/2023 - "Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation."

02/01/2020 - "Key messages • Iguratimod was effective for relapsed or refractory IgG4-RD patients. "
02/01/2020 - "To evaluate the therapeutic efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease (IgG4-RD). "
02/01/2020 - "Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease."
08/01/2019 - "The purpose of this study is to evaluate the therapeutic efficacy and safety of iguratimod plus corticosteroid as bridge therapy in the treatment of mild immunoglobulin G4-related disease (IgG4-RD). "
08/01/2019 - "Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial."

09/01/2020 - "Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast-to-myofibroblast transition."
10/01/2021 - "Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-α in mice."
04/01/2019 - "To investigate the potential therapeutic efficacy of iguratimod (IGU) on bleomycin (BLM)-induced pulmonary fibrosis in mice. "
09/01/2022 - "Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation."
07/01/2021 - "Iguratimod is a new kind of synthetic small molecule disease modified anti-rheumatic drug with good efficacy for rheumatoid arthritis (RA) treatment; meanwhile, it exhibits potency to alleviate alveolar inflammation and pulmonary fibrosis. "

08/01/2022 - "Iguratimod (T-614), exerting a powerful anti-inflammatory ability, has therapeutic efficacy in multiple autoimmune diseases. "
11/01/2019 - "Iguratimod could have a broader application to treat B cell-related autoimmune diseases in clinics."
01/01/2019 - "Herein, we have highlighted the role of iguratimod in autoimmune diseases and bone protection. "
01/01/2019 - "Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology."
01/01/2018 - "The PK profile and metabolic effects of iguratimod support further clinical development for its application in treating autoimmune diseases."